B cell chronic lymphocytic leukaemia
Adult: As 30 mg/mL solution: Initially, 3 mg daily via infusion over 2 hours. Repeat dose daily until tolerated then increase gradually to 10 mg daily; if tolerated, start maintenance dose of 30 mg 3 times weekly given on alternate days (dose escalation usually takes 3-7 days). Total treatment duration (including dose escalation): 12 weeks. Premedicate with antihistamine and paracetamol before dosing. Administer prophylaxis for herpes virus infections and Pneumocystis jirovecii pneumonia (PCP) and continue for a minimum of 2 months after therapy. Dosing interruption or discontinuation, or infusion time extension may be required according to individual safety or tolerability (refer to detailed product guideline).
Relapsing-remitting multiple sclerosis
Adult: In patients with highly active disease despite full and adequate treatment course with at least 1 disease modifying therapy, or in patients with rapidly evolving severe cases (≥2 disabling relapses in 1 year, and with ≥1 Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load compared to a previous MRI). As 12 mg/1.2 mL solution: Initial treatment course: 12 mg daily for 5 consecutive days (60 mg total dose). 2nd treatment course: 12 mg daily for 3 consecutive days (36 mg total dose), given 12 months after the initial treatment course. Up to 2 additional treatment courses may be considered as needed: 12 mg daily for 3 consecutive days (36 mg total dose), given at least 12 months after the prior treatment course. Doses are administered via infusion over 4 hours. Premedicate with corticosteroids prior to dosing. Give oral antiviral prophylaxis for herpes infections on the 1st day of each treatment course and continue for a minimum of 1 or 2 months after therapy. Dosing interruption or discontinuation, or infusion time extension may be required according to individual safety or tolerability (refer to detailed product guideline).